NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $10.75 +0.09 (+0.84%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$10.76 +0.01 (+0.09%) As of 07/25/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Adaptive Biotechnologies Stock (NASDAQ:ADPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADPT alerts:Sign Up Key Stats Today's Range$10.54▼$10.8550-Day Range$8.84▼$12.1652-Week Range$3.85▼$12.43Volume1.39 million shsAverage Volume2.08 million shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$10.57Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreADPT MarketRank™: Adaptive Biotechnologies scored higher than 56% of companies evaluated by MarketBeat, and ranked 487th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 4 research reports in the past 90 days.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.92) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 7.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.12% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 13.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.79 Percentage of Shares Shorted7.12% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 13.44%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.28 News SentimentAdaptive Biotechnologies has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.MarketBeat Follows11 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,977.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Stock News HeadlinesAdaptive Biotechnologies' (NASDAQ:ADPT) investors will be pleased with their strong 161% return over the last yearJuly 24 at 9:26 PM | finance.yahoo.comAdaptive Biotechnologies Corporation (ADPT) Rose on Solid ResultsJuly 23 at 4:35 PM | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. July 26 at 2:00 AM | Crypto 101 Media (Ad)Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 19, 2025 | americanbankingnews.comHow AI is Transforming Language Learning: From Static Lessons to Adaptive InstructionJuly 18, 2025 | msn.comAdaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025July 15, 2025 | globenewswire.comPeacock Greenlights Paralympics Docuseries ‘Adaptive’; Sets Premiere DateJuly 12, 2025 | msn.comAdaptive Biotechnologies Corporation (ADPT) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $5.99 on January 1st, 2025. Since then, ADPT stock has increased by 79.5% and is now trading at $10.75. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced its quarterly earnings data on Thursday, May, 1st. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.08. The firm's revenue was up 25.2% on a year-over-year basis. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' top institutional shareholders include Aberdeen Group plc (0.68%), Robertson Stephens Wealth Management LLC (0.10%), US Bancorp DE (0.08%) and Exchange Traded Concepts LLC (0.05%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Julie Rubinstein, Tycho Peterson, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, R Mark Adams, Stacy L Taylor, Robert Hershberg and Michelle Renee Griffin. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/01/2025Today7/26/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADPT CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees790Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$10.57 High Price Target$15.00 Low Price Target$6.00 Potential Upside/Downside-1.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$159.49 million Net Margins-74.84% Pretax Margin-74.87% Return on Equity-62.79% Return on Assets-24.55% Debt Debt-to-Equity RatioN/A Current Ratio2.92 Quick Ratio2.82 Sales & Book Value Annual Sales$178.96 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book7.85Miscellaneous Outstanding Shares151,920,000Free Float142,194,000Market Cap$1.63 billion OptionableOptionable Beta1.83 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:ADPT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.